To explore the activity of IO in preterminally ill cancer patients, in 2016, we designed a translational exploratory study in end-stage patients suffering from colon, breast, renal and prostate cancers treated with metronomic cyclophosphamide (CTX), low dose interleukin-2 (IL-2) and radiation (RT). This evidence concerns the gene IL2 and Familial prostate cancer.